Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia

Imatinib mesylate (IM) is the first line therapy against Chronic Myeloid Leukemia, effectively prolonging overall survival. Because discontinuation of treatment is associated with relapse, IM is required indefinitely to maintain operational cure. To assess minimal residual disease, cytogenetic analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagani, Ilaria S., Spinelli, Orietta, Mattarucchi, Elia, Pirrone, Cristina, Pigni, Diana, Amelotti, Elisabetta, Lilliu, Silvia, Boroni, Chiara, Intermesoli, Tamara, Giussani, Ursula, Caimi, Luigi, Bolda, Federica, Baffelli, Renata, Candi, Eleonora, Pasquali, Francesco, Lo Curto, Francesco, Lanfranchi, Arnalda, Porta, Fulvio, Rambaldi, Alessandro, Porta, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278316/
https://www.ncbi.nlm.nih.gov/pubmed/25594053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278316/
https://www.ncbi.nlm.nih.gov/pubmed/25594053

Ejemplares similares